Search
Hylenex (Wydase, Amphadase, Vitrase, Hydase, hyaluronidase)
Tradenames: Wydase, Amphadase, Vitrase, Hydase, Hylenex (recominant)
Indications:
1) to increase the dispersion & absorption of other drugs
2) increase the absorption of parenteral fluids given by hypodermoclysis
3) enhance diffusion of locally irritating or toxic drugs in the management of IV extravasation
Contraindications: Caution:
- 0.02 mL intradermal test dose for sensitivity prior to administration
Dosage:
1) management of IV extravasation
- reconstitute 150 unit vial of lyophylized powder with mL of normal saline
- take 0.1 mL of this solution & dilute with 0.9 mL of normal saline to yield 15 units/mL
- five 0.2 mL injections are made SC or intradermally into the extravasation site at the leading edge using a 25 or 26 gauge needle
- change needle after each injection
2) hypodermoclysis
- add 15 units to each 200 mL of IV fluid to be administered by SC route
- children: limit volume of single clysis to 200 mL
3) absorption & dispertion of drugs
- 150 units added to vehicle containing the drug
Injection: (lyophylized) 150 units
Injection: (solution) 150 units/mL (1 mL)
Amphadase, Hydase (bovine), Vitrase (ovine), Hylenex (human)
Adverse effects:
- uncommon (< 1%)
- tachycardia, hypotension, dizziness, urticaria, erythema, nausea/vomiting, chills
Mechanism of action:
- hyaluronoglucosaminidase (hyaluronidase)
Related
intravenous (IV) extravasation
General
hyaluronoglucosaminidase; hyaluronidase (HYAL)
metabolic agent (metabolic modifier)
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
Component-of
hylenex/pertuzumab/trastuzumab
hylenex/rituximab